Accessibility StatementSkip Navigation Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million Management Commentary Nadav Kidron, Chief Executive Officer of Oramed, commented: "Our disciplined investment strategy is delivering strong results. The complete $100 million cash repayment from Scilex, combined with substantial unrealized gains from our Alpha Tau position an other investments, has driven our $65 million net income and positioned us with ...

In the event that the Rights become exercisable due to the triggering ownership threshold being crossed, each Right will entitle its holder to purchase, at the Right's exercise price, a number of shares of Common Stock (or cash, other assets, debt securities of the Company, or any combination thereof equivalent in value thereto) with an aggregate value equal to twice the Right's exercise price. Rights held by the triggering person will become void and will not be exercisable to purchase shares at the reduce ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S ...

Share Repurchase and Financial Management - On October 20, 2025, Oramed Pharmaceuticals Inc. repurchased 1,155,367 shares at a price of $2.23 per share, totaling $2,576,468.41[4] - The repurchase agreement reflects the company's commitment to managing its capital structure effectively[4] - The share repurchase and termination of the joint venture are part of the company's strategic adjustments in response to market conditions[4][7] Joint Venture and Strategic Decisions - The company terminated its Joint Venture Agreement with HTIT Biotech due to unmet closing conditions, effective October 23, 2025[7] - The company continues to explore opportunities for market expansion and new product development despite recent challenges[7] Financial Information and Cautionary Notes - Preliminary financial information as of September 30, 2025, was issued in a Shareholder Letter, but it is unaudited and subject to future adjustments[8] - The company cautioned that the financial information provided should not be relied upon for investment decisions, as it may materially vary from actual results[9] - The company has not completed its quarter-end financial close processes, indicating potential changes in reported results[9] - The financial information disclosed is based on management's estimates and assumptions, highlighting the preliminary nature of the data[9] Business Strategy Focus - The company remains focused on its oral drug delivery technology as a core aspect of its business strategy[6]

Core Insights - Oramed Pharmaceuticals has made significant advancements in its operations and strategic initiatives, focusing on long-term shareholder value creation [2][8] - The company has identified high-responder subgroups in its oral insulin program, showing potential for over 1% reduction in HbA1c, which enhances its regulatory and commercial positioning [4][17] - Oramed is pursuing a 60-patient trial in the U.S. to validate its oral insulin formulation, aiming for cost-effective evidence generation [5][17] Oral Insulin Program - The oral insulin program has shown promising results in high-responder subgroups, particularly among participants with lower BMI and older demographics [4] - A new U.S.-based trial is being initiated to validate the oral insulin formulation and refine patient selection criteria for future regulatory submissions [5] Investment Portfolio - Oramed has strategically invested in various biomedical companies, including a $99.5 million loan to Scilex Holdings, which has returned $95.5 million to date, with total expected returns of approximately $170 million [7][9] - The company invested $36.9 million in Alpha Tau Medical, with a current valuation of approximately $64.8 million, reflecting a gain of $27.1 million [9][10] - Oramed has also invested $7 million in BioXcel Therapeutics and $1.5 million in Pelthos Therapeutics, with significant gains realized in both investments [12][13] Growth Initiatives - The company is actively pursuing partnerships with strong companies to unlock market potential and drive value creation [15] - Oramed's diversified investment strategy has led to substantial returns while maintaining focus on its core oral insulin program [3][17] Financial Performance - As of September 30, 2025, Oramed's total cash and assets have grown to approximately $210 million, demonstrating effective capital deployment despite investing $17.8 million in R&D [16]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Em ...

Core Insights - Alpha Tau Medical Ltd. has successfully closed a registered direct offering, raising approximately $36.9 million through the sale of 14,110,121 ordinary shares at a price of $2.612 per share [1][2] - The investment comes at a crucial time for Alpha Tau, which is experiencing significant growth with four active U.S. trial approvals and expansion into multiple internal organ applications [1][4] - Alpha Tau plans to utilize the net proceeds for general corporate purposes, including research and development, manufacturing expansion, and potential commercialization of its product candidates [2] Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and commercialization of the Alpha DaRT technology for treating solid tumors [6] - The Alpha DaRT technology involves intratumoral delivery of radium-224 to enable targeted alpha-irradiation of tumors, aiming to destroy cancer cells while sparing healthy tissue [7] Strategic Partnership - An affiliate of Oramed Pharmaceuticals has entered into an agreement to provide Alpha Tau with strategic services, including investor and public relations, over the next three years [3] - Both companies express strong confidence in the partnership, with expectations for significant advancements in clinical and commercial efforts [4]

Core Insights - Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, acquiring approximately 14.1 million shares at a price of $2.612 per share, aimed at supporting Alpha Tau's innovative cancer therapy technology [1][2] - The partnership combines Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology, enhancing both companies' capabilities in therapeutic delivery [1][3] - Oramed will provide strategic guidance and capital markets expertise to Alpha Tau through a three-year service agreement, which includes appointing two directors to Alpha Tau's Board [2][3] Company Overview - Oramed Pharmaceuticals specializes in oral delivery solutions for drugs typically administered via injection, utilizing its proprietary Protein Oral Delivery (POD™) technology to enhance drug integrity and absorption [4] - Alpha Tau Medical, founded in 2016, focuses on the research and development of the Alpha DaRT® technology for treating solid tumors, initially developed by professors from Tel Aviv University [5] Strategic Goals - The collaboration is expected to accelerate Alpha Tau's clinical trials across four indications in the U.S., expand manufacturing capacity, and enhance commercialization efforts [1][2] - Both companies share a vision of transforming therapeutic delivery methods, with Oramed focusing on oral administration and Alpha Tau on targeted radiation therapy [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Emplo ...